Apoptotic protein expression in favorable-histology Wilms tumor correlates with tumor recurrence
- 21 October 2010
- journal article
- research article
- Published by Springer Nature in Pediatric Surgery International
- Vol. 27 (3) , 303-308
Abstract
Purpose Outcome for patients with Wilms tumor (WT) with favorable histology is good. Deletions of chromosomes 1p and 16q impart a poorer outcome. Value of apoptotic protein expression is not clear. Methods Expression of four immunohistochemically detectable apoptosis-regulating proteins (bcl-2, bcl-x, bax and p53) were analyzed in 30 specimens of WT and compared to recurrence and recurrence-free survival (RFS). Results The 30 patients included ranged from 4 to 72 months in age (mean 31). The mean available follow-up was 35.3 months (range 1–54). Six patients developed recurrence. The 5-year RFS for blastema-predominant tumors was 40% as compared to 91% for triphasic histology which was significant (p = 0.048). The 5-year RFS in patients with bcl-2 negative tumors was 63% as compared to 100% for bcl-2 positive tumors, the difference being significant (p = 0.019). The 5-year RFS in patients with p-53 positive tumors was 27% as compared to 91% for p-53 negative tumors; however, this difference in the RFS was not statistically significant (p = 0.143). bax and bcl-x expression were not related to the RFS. Conclusions Tumors that are bcl-2 negative have a relatively higher recurrence rate and a poorer RFS. They may benefit from a more intensive follow-up regime for early detection of recurrence.Keywords
This publication has 29 references indexed in Scilit:
- Loss of Heterozygosity for Chromosomes 1p and 16q Is an Adverse Prognostic Factor in Favorable-Histology Wilms Tumor: A Report From the National Wilms Tumor Study GroupJournal of Clinical Oncology, 2005
- Significance of Proto-Oncogene Bcl-XS/L Expression in Wilms TumorRenal Failure, 2005
- Reduction of postoperative chemotherapy in children with stage I intermediate-risk and anaplastic Wilms' tumour (SIOP 93-01 trial): a randomised controlled trialThe Lancet, 2004
- Doxorubicin for favorable histology, Stage II–III Wilms tumorCancer, 2004
- Results of the SIOP 93-01/GPOH Trial and Study for the Treatment of Patients with Unilateral Nonmetastatic Wilms TumorKlinische Padiatrie, 2004
- Clinical and biologic significance of nuclear unrest in Wilms tumorCancer, 2003
- New Developments in the Pathology of Wilms Tumor: Pediatric OncologyCancer Investigation, 1997
- Anaplastic Wilms' tumour, a subtype displaying poor prognosis, harbours p53 gene mutationsNature Genetics, 1994
- Bcl-2 and the regulation of programmed cell deathJournal of Cell Biology, 1994
- Aberrant expression of the tumour suppressor gene p53 is very frequent in Wilms' tumoursThe Journal of Pathology, 1992